BCDA stock news · BioCardia, Inc.
Get alerts for BCDA
Follow BioCardia, Inc. (BCDA) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for BCDABioCardia, Inc.: Other Events (BCDA)
Good for BCDABioCardia completed its clinical consultation process with Japan's PMDA for CardiAMP and is moving toward an approval application. This is a positive step, though approval has not been reported.
BioCardia, Inc.: Other Events (BCDA)
Good for BCDABioCardia says the FDA accepted its Helix catheter review package, with a meeting expected this quarter. This is progress toward clearance, but the catheter is not cleared yet.
BioCardia, Inc. shares news about the CardiAMP HF II Trial at a heart meeting.
NeutralBioCardia reported presenting the CardiAMP HF II study design at a heart-failure meeting. The filing gives no patient results, so it does not change the company’s outlook.
BioCardia, Inc. shares news about its FDA and PMDA submissions.
NeutralBioCardia confirmed timing and updated FDA and PMDA submissions; the filing lacks substantive detail, so it does not change our reading of BioCardia.
12 health care stocks changed a lot after the market closed on Wednesday.
NeutralBioCardia dropped 8.01% after hours in the report, but the story lacks operational details, leaving the company's view intact.
BioCardia, Inc.: Other Events (BCDA)
NeutralBioCardia announced its CEO will speak at a September investor conference; the release provides visibility but no scientific or financial data, so the filing is neutral for the company.
BioCardia, Inc. faces potential delisting after failing to meet ongoing listing criteria; listing transfer initiated (BCDA).
Bad for BCDABioCardia, Inc. has filed a Form 8-K indicating that it has received a notice of delisting from the stock exchange due to not meeting continued listing requirements. This news is significant as it raises concerns about the company's financial health and future viability, likely leading to a bearish sentiment among investors.